Centre caps margins on cancer drugs, prices may fall up to 70%

What is a trade margin, and what does it mean to cap it at 30%?

A trade margin is the amount added as a medicine moves through the supply chain, between the price paid to obtain it and the price charged onward. It helps cover distribution and selling costs, but very large margins can sharply increase what patients pay. The new rule limits this margin to 30% for covered non-scheduled anti-cancer drugs.

The article gives a striking example. A cancer medicine reportedly reached retailers at about Rs 2,700 but carried an MRP of Rs 27,000. Under trade-margin rationalisation, the allowed margin is restricted, so the printed maximum price can fall when the earlier mark-up is excessive. The exact reduction depends on the medicine’s existing trade margin.

The government expects some MRPs to drop by up to 70%. It also says the measure should preserve availability while making treatment more affordable. The rule covers branded and generic medicines, and domestic and imported products, outside scheduled price controls.

Which cancer medicines are covered by the new rule?

The new rule applies to non-scheduled anti-cancer drugs. These are cancer medicines that fall outside the scheduled price-control framework mentioned in the article. The policy is therefore aimed at medicines whose trade margins were not already covered by the same scheduled pricing controls.

Its coverage is broad. It includes branded and generic medicines made in India and imported medicines, and patented and non-patented anti-cancer drugs. The common condition is that they are non-scheduled and used for cancer treatment. This makes the measure wider than the earlier intervention covering 42 medicines.

The government says the expanded approach is intended to curb excessive mark-ups while keeping medicines available. It complements existing controls: as of March 2026, the NPPA had effective ceiling prices for 131 anti-cancer drugs. The article does not list individual medicines or say that every cancer drug will receive the same price reduction.

How much could patients’ prices fall, and how much money could the measure save each year?

The government estimates that the expanded 30% trade-margin cap could reduce the maximum retail prices of some non-scheduled anti-cancer medicines by up to 70%. This is a possible maximum, not a uniform cut for every medicine. The result will depend on how high each product’s existing trade margin is before the rule takes effect.

The expected financial benefit is substantial. The Centre estimates annual savings of around Rs 2,500 crore for patients. The article links these savings to lower MRPs after excessive mark-ups are reduced across the supply chain. The policy covers branded and generic products, and domestic and imported medicines.

The earlier 2019 intervention provides context. It reduced the MRPs of 526 brands by an average of around 50% and generated estimated annual savings of about Rs 984 crore. The new measure is broader, but the article presents its figures as government estimates, not guaranteed savings.

Why did the Supreme Court question the pricing of cancer medicines?

The Supreme Court questioned cancer-drug pricing because patients could face very large differences between a medicine’s supply price and its MRP. The court focused on whether such mark-ups were justified and why a common margin could not be considered for medicines. Its scrutiny placed affordability and transparency at the centre of the pricing debate.

The court examined a reported example in which a cancer medicine was supplied to retailers for around Rs 2,700 but carried an MRP of Rs 27,000. That was nearly a ten-fold difference. The Bench also raised concerns about corporate hospitals requiring patients to buy medicines from in-house pharmacies, especially when government schemes reimburse treatment.

The court floated a possible 16% framework, similar to the retailer margin used for scheduled formulations. It did not order a nationwide 16% cap. The government instead announced a 30% cap for non-scheduled anti-cancer drugs. The matter was scheduled for October 12.

What happened when the government previously capped margins for 42 non-scheduled anti-cancer medicines in 2019?

In 2019, the National Pharmaceutical Pricing Authority capped trade margins at 30% for 42 non-scheduled anti-cancer medicines. This was an earlier use of the Trade Margin Rationalisation approach. It targeted high trade margins rather than limiting the policy only to medicines already covered by scheduled price controls.

The government says the intervention reduced the MRPs of 526 brands by an average of around 50%. That means the impact extended across many brands linked to the 42 medicines. The stated mechanism was straightforward: restricting the trade margin reduced the amount that could be added between the medicine’s supply point and its final listed price.

The government estimated annual patient savings of about Rs 984 crore from that earlier action. The latest decision expands the same approach to the wider universe of non-scheduled cancer medicines. It could produce larger savings, but the article gives the new figure as an estimate of around Rs 2,500 crore annually.

What other measures can reduce cancer-drug costs besides limiting trade margins?

Limiting trade margins is one route to cheaper cancer medicines, but the government is using other tools too. The article identifies effective ceiling prices, customs-duty reductions, and schemes such as Jan Aushadhi. Each can reduce the amount patients pay through a different part of the medicine-pricing system.

Ceiling prices place a maximum price on medicines covered by that control. As of March 2026, the NPPA had effective ceiling prices for 131 anti-cancer drugs. Customs-duty reductions can lower costs associated with imported medicines or inputs. Jan Aushadhi is another government scheme the article identifies as improving affordability.

These measures can work alongside the 30% cap. The cap addresses excessive trade mark-ups on non-scheduled medicines, while ceiling prices directly control prices for covered drugs. The article does not quantify the savings from the customs-duty reductions or Jan Aushadhi measures. It does show that cancer affordability is being addressed through several mechanisms.

How does the medicine supply chain—from manufacturer to retailer to patient—determine the final price of a drug?

The supply chain connects the manufacturer to distributors, retailers or hospital pharmacies, and finally the patient. Each stage may add a trade margin to cover its role in moving and selling the medicine. The total of these additions, along with the medicine’s underlying price, helps determine the final price or MRP seen by patients.

The article highlights how large the gap can become. One cancer drug was reportedly supplied to retailers for around Rs 2,700 but carried an MRP of Rs 27,000. The Supreme Court treated this nearly ten-fold difference as a serious pricing concern. Corporate hospitals’ in-house pharmacies also came under scrutiny when patients were required to buy medicines there.

The 30% rule acts on the trade-margin part of this chain. It limits the margin for covered non-scheduled anti-cancer medicines, which can reduce MRPs when earlier mark-ups were high. It does not mean every medicine will fall by 70%. The article says the reduction depends on existing trade margins.

What could the 30% trade-margin cap mean for the availability of non-scheduled cancer medicines and for manufacturers, distributors, and hospital pharmacies?

For patients, the intended consequence is lower prices for non-scheduled cancer medicines. The government says the rule will curb excessive mark-ups, make treatment more affordable, and ensure that medicines remain available. The scale of the price change will vary, because it depends on each medicine’s existing trade margin.

Manufacturers, distributors, retailers, and hospital pharmacies will have less room to add trade margin to covered products. The policy applies to branded and generic medicines, domestic and imported products, and patented and non-patented drugs. The Supreme Court had separately questioned corporate hospitals requiring purchases from in-house pharmacies, especially under government reimbursement schemes.

The article does not report how manufacturers or distributors will change their prices, profits, or supply decisions. It also does not provide evidence yet about availability after the expanded rule. The government’s stated aim is to combine affordability with continued access. The policy extends the 2019 Trade Margin Rationalisation approach to a much wider group of medicines.